Pelthos Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Pelthos reported Q3 2026 Zelsuvie net product revenue of $15.2 million, up 114% year over year from Q3 of 2025 and compared with $15.4 million in Q2 of 2026.
- The company reported 12,384 prescriptions in Q3, up 4% from 11,925 in Q2 and 365% year over year, with 4,942 unique prescribers at quarter-end.
- Since launch in July 2025, Pelthos reported $57.5 million of aggregate net product revenue; management also reported more than 40,000 units dispensed and more than 31,000 patients treated, while its commercial update cited more than 34,000 patients treated.
- As of October 2026, Zelsuvie had formulary coverage across 127 million commercially covered lives, approximately 70% of commercially covered lives, and Medicaid coverage of more than 70 million lives, representing 100% of covered lives.
- Q3 2026 gross-to-net was 31.5%, compared with 29.6% in Q2; cost of goods sold was $1.7 million, SG&A was $18.8 million, net loss was $7.9 million, and adjusted EBITDA was negative $5.6 million.
- Cash was $17.7 million and accounts receivable was $13.4 million as of September 30th, 2026; working capital was $24.6 million.
- Pelthos reported signing a Castle Creek Biosciences transaction on October 30th, with the expected deal close in the first quarter of next year.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and welcome to Pelthos Therapeutics 2026 third quarter financial results conference call. Pelthos issued a press release today announcing its financial results for the quarter ended September 30, 2026. A copy can be found in the Investor Relations tab on the company's corporate website, www.pelthos.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, projections, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from the company's current expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this conference call.
While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. As a reminder, this conference call is being recorded and will remain available for 90 days. I'd now like to turn the call over to Scott Plesha, Chief Executive Officer.
Scott, you may begin. Good morning, everyone, and welcome to Pelthos Therapeutics 2026 third quarter financial results conference call.
Pelthos issued a press release today announcing its financial results for the quarter ended September 30, 2026. A copy can be found in the Investor Relations tab and on the company's corporate website at www.pelthos.com. Before we begin, I'd like to remind you during today's call, statements about the company's future expectations, projections, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from the company's current expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this conference call.
While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. As a reminder, this conference call is being recorded and will remain available for 90 days. I'd now like to turn the call over to Scott Plesha, Chief Executive Officer.
Scott, you may begin. Thank you, Mike, and good morning, everyone.
We're pleased to be here with you today to share our third quarter 2026 financial and operational results and highlights. I'm joined today by Peter Greenleaf, our Executive Chairman, John Gay, Chief Financial Officer, and Sai Rangarao, our Chief Commercial Officer. The third quarter of 2026 was a successful one for Pelthos, with progress made in several key areas. During Q3, we generated Zelsuvmi net revenue of $15.2 million, which represents a year-over-year increase of 114% from Q3 of 2025. In five quarters since commercial launch, we have dispensed over 40,000 units of Zelsuvmi and treated over 31,000 patients.
In early October, we announced that we had signed an agreement with a major PBM to open access to Zelsuvmi, covering 24 million commercial covered lives, and received a formulary update enhancing access to Zelsuvmi with a regional health plan that covers approximately 3 million lives. We believe that these improvements in formulary access will be important to the continued growth of Zelsuvmi. With these improvements, Zelsuvmi now has formulary coverage across 127 million, or approximately 70% of commercially covered lives, and strong Medicaid coverage of more than 70 million, or 100% of covered lives. We continue to make progress in establishing the manufacturing of our two other highly complementary products, Xepi and XEGLYZE. We are currently building launch inventory for Xepi for the treatment of impetigo and expect to begin promoting it to our current customer base by the end of Q1 2027.
With XEGLYZE for head lice, we have initiated the manufacturing of API and expect to commercially launch it by the end of Q3 2027. We're excited about the impending launches of Xepi and XEGLYZE, as we expect they'll have a meaningful call overlap for our existing field force, which we expect will provide the company with greater operational and financial leverage from our existing team and infrastructure. Before we cover our commercial and financial results, I want to spend a few minutes on the exciting Castle Creek Biosciences transaction we announced on October 30th. While I'm limited in what I can say given that the S-4 has not yet been filed, I believe it's important to comment on why we have such strong conviction in this acquisition and in the long-term opportunity it creates for Pelthos and our shareholders.
Since our formation in July of last year, our strategy has been focused on building a strong commercial organization in dermatology with the physician relationships, commercial infrastructure, and manufacturing expertise necessary to succeed in bringing innovative therapies to market. Having made substantial investments in establishing that foundation, we see great synergy and an opportunity to leverage these capabilities across a broader portfolio, expanding our potential future revenue base and generating greater revenue on the investments we've already made. Castle Creek represents a particularly strong fit with that strategy. Its lead candidate is D-Fi, an investigational redosable gene-modified cell therapy being developed for dystrophic epidermolysis bullosa, or DEB, a rare lifelong disease characterized by extremely fragile skin, chronic wounds, and serious complications. D-Fi has been granted orphan drug designation, and once the transaction closes, we expect to continue development of its phase III clinical trials.
Patients who suffer from DEB live with intense wound burden, frequently accompanied by serious complications, including a greatly increased risk of developing squamous cell carcinoma, which is the leading cause of death in DEB patients. The wound burden never goes away, creating sustained demand for multiple therapies that can close wounds and keep them closed. The market for DEB therapies has already proven its commercial potential. The first gene therapy approved for DEB, a weekly topical treatment launched in 2023, generated $127 million in global net revenue in the third quarter of this year, up 30% from a year ago, and more than $1.1 billion since launch, with over 760 U.S. reimbursement approvals to date. The pace of this launch demonstrates that payers recognize the severity of this rare disease.
Coverage has been broad, revenue per patient is high, and gross-to-net adjustments have been modest relative to many specialty markets. We also believe there remains significant unmet need in this disease state, and so far, our conversations with KOLs and healthcare providers who treat DEB have consistently highlighted the need for further treatment options. We believe D-Fi, upon approval, can leverage this need and capture a meaningful share of the market because it offers a differentiated approach. It uses the patient's own skin cells engineered to produce type VII collagen and delivered by intradermal injection directly into the wound. It is designed to be redosed with treatment sessions every eight weeks in the planned phase III trial.
We expect the treatment paradigm with DEB to increasingly involve more than one therapy across different wounds and stages of the disease, and we see a clear role for D-Fi as a standalone first-line treatment, as well as being used alongside existing treatment options. This opportunity is also not limited to the U.S. We believe that approximately one-half of the market for DEB treatments is outside the U.S., and our agreement with Castle Creek includes rest-of-the-world rights to D-Fi as well. This is exactly the kind of high-value, specialist-driven market where we believe our commercial model provides a great deal of synergy. It is concentrated, it is served by dermatologists we already have relationships with, particularly in pediatric dermatology, and the economics per patient support an efficient, focused launch. Beyond D-Fi, Castle Creek's proprietary fibroblast-based technology adds a cell and gene therapy capability to Pelthos' existing NITRICIL manufacturing platform.
Together with our three FDA-approved products, Zelsuvmi, Xepi, and XEGLYZE, the combined company will offer a more diversified portfolio spanning marketed, launch-stage, and late-stage assets across multiple therapeutic modalities. This combination of complementary capabilities is central to the strategic rationale of the transaction. By leveraging our existing manufacturing expertise and commercial infrastructure, we believe we may be able to accelerate the development and, if approved, launch of this product candidate. If successful, we believe this program has the potential to expand our revenue base and create long-term value for our shareholders. But the potential of this transaction extends beyond the addition of a single development asset, no matter how great D-Fi's potential. This transaction positions Pelthos to be a stronger, more diversified biotech company, poised to pursue additional pipeline opportunities, build a broader commercial portfolio, and expand its long-term earnings potential.
A disciplined capital allocation approach remains central to this strategy, and we intend to focus on translating these opportunities into sustainable revenue while maintaining the financial discipline necessary to generate attractive long-term returns. In short, we are extremely enthusiastic about the potential of D-Fi and are confident that the Castle Creek transaction can be a foundational pillar of the next phase of Pelthos' growth. I'll now turn it over to Sy to provide more specifics on the result of our commercial performance.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
